Sandra Colas
Overview
Explore the profile of Sandra Colas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stoupa A, Kariyawasam D, Jabot-Hanin F, Quoc A, Hanein S, Rabeony T, et al.
J Clin Endocrinol Metab
. 2025 Jan;
PMID: 39787321
Context: Congenital hypothyroidism (CH) is the most common neonatal endocrine disorder and is chiefly caused by thyroid dysgenesis (CHTD). The inheritance mode of the disease remains complex. Objectives: Gain insight...
2.
Courbebaisse M, Bourmaud A, Souberbielle J, Sberro-Soussan R, Moal V, Le Meur Y, et al.
Am J Transplant
. 2023 Jan;
23(3):366-376.
PMID: 36695682
Vitamin D sufficiency is associated with a reduced risk of fractures, diabetes mellitus, cardiovascular events, and cancers, which are frequent complications after renal transplantation. The VITALE (VITamin D supplementation in...
3.
Mejean A, Ravaud A, Thezenas S, Chevreau C, Bensalah K, Geoffrois L, et al.
Eur Urol
. 2021 Jun;
80(4):417-424.
PMID: 34187771
Background: The CARMENA trial in patients with metastatic renal cell carcinoma (mRCC) demonstrated that treatment with sunitinib alone was noninferior to cytoreductive nephrectomy (CN) followed by sunitinib (nephrectomy⬜sunitinib). Objective: The...
4.
Mejean A, Ravaud A, Thezenas S, Colas S, Beauval J, Bensalah K, et al.
N Engl J Med
. 2018 Jun;
379(5):417-427.
PMID: 29860937
Background: Cytoreductive nephrectomy has been the standard of care in metastatic renal-cell carcinoma for 20 years, supported by randomized trials and large, retrospective studies. However, the efficacy of targeted therapies...
5.
Courbebaisse M, Alberti C, Colas S, Prie D, Souberbielle J, Treluyer J, et al.
Trials
. 2014 Nov;
15:430.
PMID: 25376735
Background: In addition to their effects on bone health, high doses of cholecalciferol may have beneficial non-classic effects including the reduction of incidence of type 2 diabetes mellitus, cardiovascular disease,...